The total diagnosed prevalent cases of Pemphigus Vulgaris in the 7MM was 41,217 in 2017. Among 7MM, the United States accounted for the highest number of diagnosed prevalent cases of PV in 2017, while France had the lowest number of cases.
The market size of Pemphigus Vulgaris in 7MM was found to be USD 181.78 Million in 2017, which is expected to increase during the forecast period 2017-2030.

Approval of MabThera/Rituxan, increasing awareness, rising prevalence rates, updated diagnostic and treatment guidelines are some of the key factors expected to drive the PV market forward in the coming years.
The key pharma companies in the Pemphigus Vulgaris Market include Principia Biopharma, Novartis/ MorphoSys, Argenx, Topas Therapeutics, and many others.

For more detailed information on Pemphigus Vulgaris Market, visit:
https://www.delveinsight.com...